Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
The Bing Center for Waldenström's Macroglobulinemia encompasses a large, international team of laboratory-based and clinical investigators who are striving to find more effective therapies for Waldenström's macroglobulinemia and, someday, a cure.
Steven P. Treon, MD, PhD, director, Bing Center for Waldenström's Macroglobulinemia
Treon's main research interests focus on understanding the genetic basis and pathogenesis of Waldenström's and the development of novel therapeutics. He serves on the editorial boards of Journal of Clinical Oncology,
Blood, Clinical Cancer Research, and The Lancet. He has been honored with several research and academic awards, including the Robert A. Kyle Award for Waldenström's.
Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström's MacroglobulinemiaCastillo's clinical program runs a series of prospective clinical trials using non-chemotherapeutic
regimens, and has developed several multi-institutional efforts to study Waldenström's macroglobulinemia. He serves as a member of the NCCN panel for Multiple Myeloma, Systemic Light Chain Amyloidosis and Waldenström's Macroglobulinemia. His work
has been published in New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, and Blood.
New Patient Appointments
Catherine Flynn, NP